A selection of must-have articles
The Science and Politics of Colorectal
Cancer Screening
Politicians in developed countries have secured a certain standard of health care for the sick as well as vaccination programmes to reduce the risk of illness - cancer screening is next, with breast and cervical cancer screening programmes at the top of the list.
Screening for Colorectal Cancer - Advantages and Limitations of the Different Screening Options
Evidence-based CRC screening guidelines recommend that all asymptomatic, average-risk women and men be offered screening for CRC beginning at age 50.
New Advances in the Chemotherapy of Metastatic Colorectal Cancer
When advanced metastatic disease (stage IV) is diagnosed, the prognosis is poor with five-year survival in the 5% to 8% range. This survival rate has remained essentially unchanged over the past 35–40 years.
Keeping you up to date with the latest clinical trial information
The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®) in first-line treatment of metastatic colorectal cancer. The trial will investigate two regimens of FLOX plus cetuximab, in which FLOX is given continuously or intermittently, compared to standard FLOX without cetuximab.
Keeping you up to date with the latest clinical trial information
The follow up of colorectal cancer after curative surgery has to find loco-regional relapses or synchronous metastases, and to detect adenomas and new cancer on the rest of the colon.
The increase of survival after relapse of the colorectal cancer depends on the possibility of curative action or after chemotherapy response.
This is a Phase III open-labed, multicenter, multidisciplinary, randomised study, comparative 2-arms of 188 patients (i.e. 376 of total patients).
Study period (date of first inclusion/Last inclusion): 3 years. Follow up : 3 years.
The primary objective is the evaluation of TEP performance in the earlier relapse detection of the colorectal cancer relapse in comparison with conventional control (including CEA levels and others classic radiological exams.)
Keeping you up to date with the latest clinical trial information
TColorectal cancer is a type of cancer that begins in the large intestine (colon) or the rectum (end of the colon). Several drugs are often given in combination to treat colorectal cancer. One of the most active treatment combinations is known as FOLFOX, which is a combination of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. Oxaliplatin is a type of platinum drug and was approved by the FDA in 2004. While generally well-tolerated, oxaliplatin may cause toxicity to the nerves, such as sensory loss or cold sensitivity.
Picoplatin is a new type of platinum drug that has shown activity with 5-FU in pre-clinical studies and has undergone extensive Phase 1 and Phase 2 testing in a variety of cancers. No significant nerve toxicity has been seen in previous studies of picoplatin.
This study will review the safety and effectiveness of FOLPI, which is the combination of 5-FU and leucovorin with picoplatin in participants with colorectal cancer.
A New Paper from the World Journal of Surgical Oncology
Research by Sarikaya and colleagues at the The Ohio State University has shown that PET is valuable to detect tumor recurrence in selected
cases who have normal CEA but clinically and/or radiologically
suspicious tumor recurrence.
FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA
| ASCO Collection |
 |
|
Highlights from ASCO 2007
|
| Guidelines Watch |
|
|
A round up of the latest Clinical Guidelines from the National Guideline Clearinghouse (NGC)
A report by the NCH summarising the recommendations for colorectal cancer screening, among individuals of varying risk for developing colorectal cancer, from the following groups:
|
